Lundbeck results hit by generic competition

10 February 2022

Shares of Danish CNS specialist Lundbeck (LUND: CO) closed down 7.4% at 148.55 kroner after it reported financial results for the fourth quarter and full year 2021.

The company posted fourth-quarter revenues of 4.1 billion kroner ($630 million), down 5% year-on-year, and a net loss of 2 million versus a profit of 553 million kroner a year ago.

For the full year, revenue reached 16.3 billion kroner, due to a decline of 5% in local currencies and to erosion on Northera (droxidopa) following loss of exclusivity and reduced contract work.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK